BiotechTube
Direct Biologics

Direct Biologics

Austin, United States· Est.
directbiologics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $35M

Overview

Direct Biologics is a private, clinical-stage biotech company founded in 2017 and headquartered in Austin, Texas. It is a pioneer in developing extracellular vesicle (EV)-based therapeutics, with a lead program, ExoFlo™, in Phase 3 trials for ARDS and earlier-stage trials for Crohn's disease and ulcerative colitis. The company has secured significant regulatory designations like RMAT, operates its own cGMP manufacturing, and is positioning itself as a leader in the emerging EV therapeutics space. Its business model is focused on therapeutic development, and it is currently in a pre-revenue stage.

Acute Respiratory Distress Syndrome (ARDS)Inflammatory Bowel DiseaseAutoimmune Diseases

Technology Platform

Proprietary platform for manufacturing extracellular vesicles (EVs) derived from adult human bone marrow mesenchymal stem cells (MSCs) under cGMP conditions. The EVs act as natural carriers of bioactive molecules for regenerative and immunomodulatory therapy.

Funding History

2
Total raised:$35M
Series B$25M
Series A$10M

Opportunities

The company's lead program in All-Cause ARDS addresses a large, critical care market with high mortality and few effective treatments, with an RMAT designation potentially accelerating its path to market.
Its EV platform technology offers a versatile 'pipeline-in-a-product' opportunity, enabling expansion into multiple inflammatory and autoimmune conditions beyond the current pipeline.

Risk Factors

The company faces significant clinical trial risk, as its value is contingent on positive data from its Phase 3 ARDS trial and other studies.
Regulatory uncertainty surrounds the novel EV therapeutic class, and the company must successfully scale cGMP manufacturing while managing cash burn as a pre-revenue private entity.

Competitive Landscape

Direct Biologics is a pioneer in the emerging extracellular vesicle therapeutics space, competing with other EV-focused biotechs and more established cell therapy companies. In ARDS and IBD, it faces competition from both approved drugs and novel biologics in development from large pharmaceutical firms, requiring it to demonstrate clear differentiation in efficacy or safety.

More companies in Regenerative Medicine →More companies in United States →